Welcome Guest
Home » Reports » Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030

Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030

Published: Nov 17, 2017
Pages: 247
Product Code: RA10094
License Type :  (Learn More)

Monoclonal antibodies have been in use for more than two decades. The first product candidate was launched in 1986; since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious diseases. However, despite their clinical and commercial successes, these therapies are known to have certain drawbacks that have had an impact on their overall efficacy, thereby, limiting their therapeutic potential. These drawbacks are related to their inherent structural complexities, high manufacturing costs, difficulties in formulation and insufficient understanding of their precise in vivo mechanisms of action.

 

The above-mentioned limitations have prompted researchers to identify alternative protein scaffold based therapeutic strategies. Amongst other novel formats, non-antibody protein scaffolds have emerged as viable alternatives, having the capability to address the existing challenges associated with classical antibody based therapies. Although the concept of non-antibody protein scaffolds was conceived more than a decade ago, this field has gained popularity in recent years. Presently, there is one approved product (Kalbitor®), and several non-antibody protein scaffold based product candidates that are being developed across various clinical and preclinical stages.Monoclonal antibodies have been in use for more than two decades. The first product candidate was launched in 1986; since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious diseases. However, despite their clinical and commercial successes, these therapies are known to have certain drawbacks that have had an impact on their overall efficacy, thereby, limiting their therapeutic potential. These drawbacks are related to their inherent structural complexities, high manufacturing costs, difficulties in formulation and insufficient understanding of their precise in vivo mechanisms of action.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030’ report provides a comprehensive study of the current market landscape of non-antibody protein scaffolds, and related drugs and diagnostics, featuring an elaborate discussion on the likely future potential of this upcoming market. Over the past few years, this burgeoning field of research has captured the interest of several players in the pharmaceutical industry. Amongst other elements, the report features:

  • An overview of the current market landscape, featuring comprehensive list of active industry / non industry players, and detailed analysis of non-antibody protein scaffold based product candidates, based on phase of development (clinical and preclinical / discovery), target therapeutic area(s), end-use (therapeutic agents, diagnostic imaging agents and diagnostic tests), type of scaffold format, route of administration (intravenous, subcutaneous, and intravitreal) and non-antibody protein scaffold technology used.
  • A review of the various non-antibody protein scaffolds that are presently available for the development of therapeutics / diagnostics, highlighting information on their developers, and structural and pharmacokinetic features. Specifically, for each scaffold type, we have captured information on size, origin of parent protein, structure, mode of randomization of scaffolds and number of disulfide bonds, type of production system used, method of selection, in vitro half-life and melting temperature.
  • A detailed comparative analysis of various non-antibody protein scaffolds, featuring two schematic representations, including [A] an insightful 2 X 2 analysis, to assess the technical strength of the non-antibody protein scaffolds, based on product competitiveness and pipeline strength, and [B] a spider-web analysis, highlighting the popularity of non-antibody protein scaffolds (those that have products in phase I and higher stages of clinical). The analysis was based on various parameters, such as the pipeline strength (number of drugs in both preclinical / clinical stages of development), end-use, number of related publications, target indications and technical strength.
  • Comprehensive profiles of marketed and clinical stage (phase I/II and above) non-antibody protein scaffold based drugs / diagnostics, highlighting details of the product, a brief history of development, mechanism of action, non-antibody protein scaffold technology used, manufacturing details, current status of development, information on clinical studies (including key clinical trial results) and target patient population. Each profile also features information on the developer, including an overview of the company, information on its finances and funding (if available), and an informed future outlook.
  • An analysis of the partnerships that have been inked between stakeholders in the industry in the recent past, covering R&D collaborations, product / technology licensing agreements, product development / commercialization agreements, mergers / acquisitions, clinical trial collaborations, manufacturing agreements and service agreements.
  • An in-depth analysis of the product pipeline, featuring an elaborate funnel analysis, highlighting the most popular targets being considered for therapeutic, as well as diagnostic purposes, along with the formats used and highest phase of development. It includes a grid analysis, representing the distribution of non-antibody protein scaffold based products (on the basis of their end-use) across various target therapeutic areas and different stages of development.
  • A detailed analysis of the developer companies, featuring three schematic representations; these include [A] a logo landscape of the various industry and non-industry players involved in the development of non-antibody protein scaffold based products, distributed on the basis of the phase of development of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, and [C] a bubble analysis comparing the leading players engaged in the generation of drugs / diagnostics, on the basis of parameters such as clinical activity (based on the number of drug candidates developed by a particular company, across different phases of development), number of partnerships established (between 2012 and 2017) and the size of the developer company.

 

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the non-antibody protein scaffolds market. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. In addition, we have provided the likely distribution of the market based on end-use (therapeutic agents and diagnostic agents), key therapeutic areas (genetic disorders, eye disorders, autoimmune disorders, oncology and others), and non-antibody protein scaffold technologies. To account for the uncertainties associated with the development of non-antibody protein scaffold based drugs / diagnostics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

 

The opinions and insights presented in the report were also influenced by discussions with senior stakeholders in the industry. These include Alastair Smith (CEO, Avacta), Kyu-Tae-Kim (Director, AbClon), Ratmir Derda (Assistant Professor, University of Alberta) and Aditya Pandey (Postdoctoral Fellow, University of Toronto). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

  1. Over 25 unique non-antibody protein scaffolds have been developed for the generation of different product candidates. Notable examples include (in alphabetical order)Affibody® (Affibody), Affimer® (Avacta), Anticalin® (Pieris Pharmaceuticals), AdnectinTM (BMS), Bicycles® (Bicycle Therapeutics), DARPin® (Molecular Partners), Kunitz Domain (Shire) and Nanofitin® (Affilogic).
  2. Around 80 product candidates (drugs / diagnostics) based on non-antibody protein scaffolds are currently under various stages of development for a diverse range of indications. A significant proportion (82%) of these candidates are in preclinical / discovery stages. Specifically, six products are in clinical evaluation (phase I/II and above); these are (in alphabetical order) abicipar pegol (Allergan and Molecular Partners), RG6206 (BMS and Roche), ABY-025 (Affibody), ABY-035 (Affibody), MP0250 (Molecular Partners), PRS-080 (Pieris Pharmaceuticals).
  3. The market landscape is well distributed across large-sized (21), mid-sized (5) and small-sized companies (8). Some of the prominent large-sized companies engaged in this domain include (in alphabetical order) Allergan, AstraZeneca, BMS, GSK, Merck, Roche, Sanofi, Servier and Shire. Mid-sized companies that are actively contributing to the development of novel non-antibody scaffold based products include (in alphabetical order) Avacta, ITM Isotopen Technologien München, Molecular Partners, Pieris Pharmaceuticals and ThromboGenics. In addition, small companies, such as (in alphabetical order) Affibody, Affilogic, Bicycle Therapeutics, Complix, Glythera, Navigo Proteins, Nordic Nanovector and Poseida Therapeutics, are also actively involved in this domain.
  4. Several universities / research organizations, either independently or in collaboration with industry players, have also contributed to the development. Examples include (in alphabetical order) Cancer Research UK, Chonnam National University, Dartmouth-Hitchcock Medical Center, Harlev Hospital, Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and University of Leeds.
  5. Currently, almost 40% of the products in the development pipeline are focused on oncological indications, including hematological cancers and solid tumors. Apart from oncology, autoimmune disorders are the most popular; in fact, close to 17% of product candidates in the pipeline are being developed for such conditions. Products are also being developed for other therapeutic areas, such as eye disorders (7%), blood disorders (6%), inflammatory disorders (5%), respiratory disorders (5%), infectious diseases (4%) and genetic disorders (3%).
  6. Nearly 50% of the products are being investigated as stand-alone scaffolds. This is followed by products identified as scaffold-bispecific fusion proteins (17%), scaffold-drug conjugates (14%), radiolabeled scaffolds drugs (7%) and scaffold-fusion drugs (7%).
  7. Around 60 partnerships were inked between various stakeholders in the industry between 2012 and October 2017. Of these, approximately 48% were R&D related deals; recent examples include Bicycle Therapeutics and Bioverativ (September 2017), Complix and Merck (July 2017), Avacta and MSKCC (November 2016), Avacta and Glythera (July 2016). Other popular types of collaborations were product / technology licensing agreements (25%), product development / commercialization agreements (13%) and mergers / acquisitions (7%).Avacta (14), Pieris Therapeutics (8), Affibody (7), Molecular Partners (6), Shire (5), Bicycle Therapeutics (4) and Complix (4),emerged as the most active companies in terms of the number of deals signed in the given time period.
  8. Our future market outlook is optimistic as we expect several new products to be approved and launched over the coming decade. We expect the market to grow at an annualized rate of ~42% till 2030. In fact, specific products, being developed for indications with very large target patient population, are likely to achieve blockbuster status (sales over USD 1 billion) and become prime contributors to the overall market’s evolution.

 

 

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the non-antibody protein scaffolds based drugs / diagnostics market in the short to mid-term and long term.

 

Chapter 3 provides a general overview of the evolution of protein based therapeutics over the last several years, featuring a brief discussion on the limitations of antibody based therapeutics and emphasizing on the need for alternative protein scaffolds. It includes a detailed description of non-antibody protein scaffolds, elaborating on their historical evolution, classification and key benefits. It also highlights major types of proteins that are usually tagged with non-antibody protein scaffolds for therapeutic, diagnostic and research purposes. In addition, the chapter features a detailed discussion on different applications of non-antibody protein scaffolds.

 

Chapter 4 provides a detailed overview of the non-antibody protein scaffold technologies identified during this study. It features a detailed discussion on the impact of various structural and pharmacokinetic features (such as size, origin of the parent protein, structure, mode of randomization and number of disulphide bonds, production system, method of selection, in vitro half-life and melting temperatures) on drug development. The chapter also presents a comparative 2 X 2 matrix analysis of non-antibody protein scaffolds that are presently under preclinical / clinical evaluation. Additionally, it features a spider-web analysis, which highlights the relative popularity of those non-antibody protein scaffolds that have products in clinical stages of development (phase I and above). The parameters considered for this analysis include pipeline strength (based on the number of drugs in both preclinical / clinical stages of development), end-use, number of publications, indication coverage and technical strength of the scaffolds.

 

Chapter 5 provides a comprehensive overview of the current landscape of the non-antibody protein scaffold based drugs / diagnostics market. It includes information on over 80 non-antibody protein scaffolds based products that are currently in various stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of the pipeline products on the basis of their phase of development, target therapeutic area(s), end-use, type of scaffold format, route of administration and non-antibody protein scaffold technology. We have also highlighted the key players that are active in this domain.

 

Chapter 6 presents elaborate profiles of drugs / diagnostic agents that are either marketed or are in advanced stages of clinical development (phase I/II and above). Each profile provides information on the history of development, mechanism of action, non-antibody protein scaffold technology, manufacturing details, current status of development, information on clinical studies, key clinical trial results, target patient population and historical sales of the products (if marketed). It also includes a brief overview of the developer, its financial information, funding details and an informed future outlook.

 

Chapter 7 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of non-antibody protein scaffolds based drugs / diagnostics that are either marketed or are in advanced stages of clinical development (phase II and above). The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key therapeutic areas (genetic disorders, eye disorders, autoimmune disorders, oncology and others), end-use (therapeutic agents and diagnostic agents), and non-antibody protein scaffolds technologies.

 

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including R&D agreements, product / technology licensing agreements, product development / commercialization agreements, merger / acquisitions and clinical trial collaborations) and the most common forms of deals / agreements that have been established between 2012 and 2017.

 

Chapter 9 presents the key insights derived from the study. It distinctly highlights the most popular targets that are being investigated for both therapeutic, as well as diagnostic purposes along with their respective types of formats and highest phase of development. The chapter also features a grid analysis, representing the distribution of non-antibody protein scaffold based products (on the basis of their end-use) across target therapeutic areas and stages of development. In addition, it features a logo landscape of industry and non-industry players engaged in the development of non-antibody protein scaffold based products, distributed based on the developmental status of pipeline candidates and size of the companies (small, mid-sized and large companies). We have also mapped the geographical presence of various industry players involved in the development of product candidates in this field. In addition, it includes a comparative analysis, presented in the form of a bubble analysis, to highlight the leading players engaged in the generation of drugs / diagnostics based on these novel non-antibody protein scaffolds. The parameters considered for this analysis include the research activity based on the company’s development pipeline (in terms of the number of drugs across different phases of development), number of partnerships established related to each company (between 2012 and 2017) and the size of the developer company.

 

Chapter 10 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

 

Chapter 11 is a collection of interview transcripts of the discussions that were held with key stakeholders in this field.In this chapter, we have presented the details of our conversations withAlastair Smith (CEO, Avacta), Kyu-Tae-Kim (Director, AbClon), Ratmir Derda (Assistant Professor, University of Alberta) and Aditya Pandey (Postdoctoral Fellow, University of Toronto).

 

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 13 is an appendix, which provides the list of companies and organizations mentioned in the report.

 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Antibodies as Therapeutic Agents
3.2.1. Structure of an Antibody
3.2.2. Antibody Therapeutics: A Lucrative Market
3.3. Need for Alternative Protein Scaffolds
3.4. Introduction and Classification of Alternative Protein Scaffolds
3.4.1. Antibody-Derived Protein Scaffolds / Engineered Antibody Fragments
3.4.2. Non-Antibody Protein Scaffolds
3.5. A Detailed Overview of Non-Antibody Protein Scaffolds
3.5.1. Evolution of Non-Antibody Protein Scaffolds
3.5.2. Classification of Non-Antibody Protein Scaffolds
3.5.3. Advantages and Limitations of Non-Antibody Protein Scaffolds 
3.6. Key Targets for Non-Antibody Protein Scaffolds 
3.7. Applications of Non-Antibody Protein Scaffolds
3.7.1. Therapeutic Applications
3.7.2. Diagnostic Applications
3.7.3. Basic and Applied Research
3.8. Future Outlook of Non-Antibody Protein Scaffolds
 
4. NON-ANTIBODY PROTEIN SCAFFOLDS: A DETAILED COMPARISON
4.1. Chapter Overview
4.2. Key Requisites for Selection of a Suitable Scaffold
4.3. Key Parameters for Drug Development using Non-Antibody Protein Scaffolds 
4.3.1. Small Size and Tissue Penetration
4.3.2. Origin of Parent Protein and Immunogenicity
4.3.3. Serum Half-Life and Renal Clearance
4.3.4. Melting Temperature and Thermodynamic Stability
4.3.5. Oral Administration
4.3.6. Multivalency and Multispecificity
4.3.7. Production System and Cost of Manufacturing
 
4.4. List of Non-Antibody Protein Scaffolds
4.4.1. Non-Antibody Protein Scaffolds: Distribution by Scaffold Class
4.4.2. Non-Antibody Protein Scaffolds: Distribution by Origin of Parent Protein
 
4.5. Non-Antibody Protein Scaffolds: 2 x 2 Matrix Analysis
4.6. Non-Antibody Protein Scaffolds: 5D Spider-Web Analysis
 
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Development Pipeline
5.2.1. Distribution by Phase of Development
5.2.2 Distribution by End-Use
5.2.3. Distribution by Therapeutic Area
5.2.4. Distribution by Type of Format
5.2.5. Distribution by Route of Administration
5.2.6. Distribution by Non-Antibody Protein Scaffold Technology
5.2.7. Distribution by Leading Players
5.3. Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Terminated / Discontinued Candidates
 
6. DRUG / DIAGNOSTIC AGENTS: PROFILES
6.1. Chapter Overview
6.2. Kalbitor® / Ecallantide / DX-88 (Shire)
6.2.1. Overview
6.2.2. History of Development
6.2.3. Mechanism of Action
6.2.4. Dosage Form, Regimen and Price
6.2.5. Technology Overview
6.2.6. Manufacturing Information
6.2.7. Current Status of Development
6.2.8. Clinical Studies
6.2.9. Key Clinical Trial Results
6.2.10. Target Patient Population
6.2.11. Historical Sales
6.2.12. Developer Overview: Shire
6.2.12.1. Financial Information
6.2.12.2. Future Outlook
 
6.3. Abicipar Pegol / AGN-150998 / MP0112 (Allergan)
6.3.1. Overview
6.3.2. History of Development
6.3.3. Mechanism of Action
6.3.4. Technology Overview
6.3.5. Current Status of Development
6.3.6. Clinical Studies
6.3.7. Key Clinical Trial Results
6.3.8. Target Patient Population
6.3.9. Developer Overview: Allergan
6.3.9.1. Financial Information
6.3.9.2. Future Outlook
 
6.4. RG6206 / RO7239361 / BMS-986089 (Roche)
6.4.1. Overview
6.4.2. Mechanism of Action
6.4.3. Technology Overview
6.4.4. Current Status of Development
6.4.5. Clinical Studies
6.4.6. Key Clinical Trial Results
6.4.7. Target Patient Population
6.4.8. Developer Overview: Roche
6.4.8.1. Financial Information
6.4.8.2. Future Outlook
 
6.5. ABY-002 / ABY-025 (Affibody)
6.5.1. Overview
6.5.2. Mechanism of Action
6.5.3. Technology Overview
6.5.4. Current Status of Development
6.5.5. Clinical Studies
6.5.6. Key Clinical Trial Results
6.5.7. Target Patient Population
6.5.8. Developer Overview: Affibody
6.5.8.1. Financial Information
6.5.8.2. Future Outlook
 
6.6. ABY-035 / AFB-035 (Affibody)
6.6.1. Overview
6.6.2. Mechanism of Action
6.6.3. Technology Overview
6.6.4. Current Status of Development
6.6.5. Clinical Studies
6.6.6. Key Clinical Trial Results
6.6.7. Target Patient Population
6.6.8. Developer Overview: Affibody
6.6.8.1. Financial Information
6.6.8.2. Future Outlook
 
6.7. MP0250 (Molecular Partners)
6.7.1. Overview
6.7.2. Mechanism of Action
6.7.3. Technology Overview
6.7.4. Current Status of Development
6.7.5. Clinical Studies
6.7.6. Key Clinical Trial Results
6.7.7. Target Patient Population
6.7.8. Developer Overview: Molecular Partners
6.7.8.1. Financial Information
6.7.8.2. Future Outlook
 
6.8. PRS-080 (Pieris Pharmaceuticals)
6.8.1. Overview
6.8.2. History of Development
6.8.3. Mechanism of Action
6.8.4. Technology Overview
6.8.5. Manufacturing Information
6.8.6. Current Status of Development
6.8.7. Clinical Studies
6.8.8. Key Clinical Trial Results
6.8.9. Target Patient Population
6.8.10. Developer Overview: Pieris Pharmaceuticals
6.8.10.1. Financial Information
6.8.10.2. Future Outlook
 
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Scope and Limitations
7.3. Forecast Methodology
 
7.4. Overall Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market
7.4.1. Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market: Distribution by Therapeutic Area
7.4.2. Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market: Distribution by End-Use
7.4.3. Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market: Distribution by Non-Antibody Protein Scaffolds
7.4.4. Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market: Distribution by Share of Drugs
 
7.5. Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market: Individual Drug Forecasts
7.5.1. Kalbitor®
7.5.1.1. Target Patient Population
7.5.1.2. Sales Forecast
 
7.5.2. Abicipar Pegol / AGN-150998 / MP0112
7.5.2.1. Target Patient Population
7.5.2.2. Sales Forecast
 
7.5.3. RG6206 / RO7239361 / BMS-986089
7.5.3.1. Target Patient Population
7.5.3.2. Sales Forecast
 
7.5.4. MP0250 / MP 0250
7.5.4.1. Target Patient Population
7.5.4.2. Sales Forecast
 
7.5.5. ABY-025 / ABY-002
7.5.5.1. Target Patient Population
7.5.5.2. Sales Forecast
 
7.5.6. ABY-035 / AFB-035
7.5.6.1. Target Patient Population
7.5.6.2. Sales Forecast
 
8. RECENT COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Non-Antibody Protein Scaffolds: List of Partnerships
8.4. Non-Antibody Protein Scaffolds: Partnership Analysis
8.4.1. Analysis by Year of Partnerships
8.4.2. Analysis by Type of Partnerships
8.4.3. Most Popular Non-Antibody Protein Scaffolds: Analysis by Number of Partnerships
8.4.4. Most Active Companies: Analysis by Number of Partnerships 
 
9. KEY INSIGHTS
9.1. Chapter Overview
9.2. Non-Antibody Protein Scaffolds Pipeline: Potential Targets / Markers
9.3. Non-Antibody Protein Scaffolds Pipeline: Therapeutic Areas
9.4. Non-Antibody Protein Scaffolds Pipeline: Developer Landscape
9.5. Non-Antibody Protein Scaffolds Pipeline: Regional Landscape (Industry Players)
9.6. Non-Antibody Protein Scaffolds Pipeline Leading Players: 3D Bubble Analysis
 
10. CONCLUSION
10.1. Non-Antibody Protein Scaffolds have Emerged as Viable Alternatives to Monoclonal Antibody based Products
10.2. With One Approved Drug and Multiple Early-Phase Candidates, the Market is Characterized by a Promising Pipeline
10.3. Variety of Product Candidates are Being Developed to Treat a Wide Spectrum of Disease Indications; Oncology is the Key Focus Area
10.4. Both Industry and Academia are Driving the Research Efforts; A Significant Proportion of the Research Activity is Concentrated in Europe
10.5. Several Stakeholders have Entered into Strategic Alliances to Advance Research and Product Development Efforts
10.6. The Approval and Launch of Multiple Late-Phase Product Candidates in the Coming Years is Anticipated to Drive the Future Market Evolution
10.7. Concluding Remarks
 
11. INTERVIEW TRANSCRIPTS
11.1. Chapter Overview
11.2. Alastair Smith, CEO, Avacta
11.3. Kyu-Tae Kim, Director, AbClon
11.4. Ratmir Derda, Assistant Professor, University of Alberta
11.5. Aditya Pandey, Postdoctoral Fellow, University of Toronto
 
12. APPENDIX 1: TABULATED DATA
 
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
 
Figure 3.1 Basic Structure of an Antibody
 
Figure 3.2 Revenues of the Top 15 Drugs, 2016 (USD Billion)
 
Figure 3.3 Antibody Derived Scaffolds: Benefits and Limitations
 
Figure 3.4 Evolution of Alternative Protein Scaffolds
 
Figure 3.5 Classification of Non-Antibody Protein Scaffolds
 
Figure 3.6 Key Benefits of Non-Antibody Protein Scaffolds
 
Figure 3.7 Types of Target Proteins for Non-Antibody Protein Scaffolds
 
Figure 3.8 Applications of Non-Antibody Protein Scaffolds
 
Figure 3.9 Key Therapeutic Areas of Non-Antibody Protein Scaffolds
 
Figure 4.1 Selection of a Suitable Scaffold: Common Steps
 
Figure 4.2 Popular Non-Antibody Protein Scaffolds
 
Figure 4.3 Non-Antibody Protein Scaffolds: Distribution by Scaffold Class
 
Figure 4.4 Non-Antibody Protein Scaffolds: Distribution by Origin of Parent Protein
 
Figure 4.5 Non-Antibody Protein Scaffolds: Product Competitiveness Analysis
 
Figure 4.6 Non-Antibody Protein Scaffolds: Spider-Web Analysis
 
Figure 5.1 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Phase of Development
 
Figure 5.2 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by End-Use
 
Figure 5.3 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Therapeutic Area
 
Figure 5.4 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Type of Format
 
Figure 5.5 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Route of Administration
 
Figure 5.6 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Non-Antibody Protein Scaffold Technology
 
Figure 5.7 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Leading Players
 
Figure 6.1 Kalbitor®: Mechanism of Action
 
Figure 6.2 Kalbitor®: Historical Sales, 2011-H1 2017 (USD Million)
 
Figure 6.3 Shire: Annual Revenues, 2012-H1 2017 (USD Billion)
 
Figure 6.4 Dyax: Annual Revenues, 2010-9M 2015 (USD Million)
 
Figure 6.5 Allergan: Annual Revenues, 2011-H1 2017 (USD Billion)
 
Figure 6.6 RG6206: Mechanism of Action
 
Figure 6.7 Roche: Annual Revenues, 2012-H1 2017 (CHF Billion)
 
Figure 6.8 Affibody: Annual Revenues, 2012-H1 2017 (SEK Million)
 
Figure 6.9 Multiple Myeloma: Global Epidemiological Distribution
 
Figure 6.10 Molecular Partners: Annual Revenues, 2011-H1 2017 (CHF Million)
 
Figure 6.11 PRS-080: Mechanism of Action
 
Figure 6.12 Pieris Pharmaceuticals: Annual Revenues, 2013-H1 2017 (USD Million)
 
Figure 7.1 Overall Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market, 2017-2030: Base Scenario (USD Billion)
 
Figure 7.2 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by Therapeutic Area
 
Figure 7.3 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by End-Use
 
Figure 7.4 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by Non-Antibody Protein Scaffold Technology
 
Figure 7.5 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by Share of Drugs
 
Figure 7.6 Kalbitor® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 7.7 Abicipar Pegol Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 7.8 RG6206 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 7.9 MP0250 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 7.10 ABY-025 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 7.11 ABY-035 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 8.1 Non-Antibody Protein Scaffolds Partnerships: Cumulative Trend by Year (2012–2017)
 
Figure 8.2 Non-Antibody Protein Scaffolds Partnerships: Distribution by Type of Partnership
 
Figure 8.3 Non-Antibody Protein Scaffolds Partnerships: Most Popular Non-Antibody Protein Scaffold Technology
 
Figure 8.4 Non-Antibody Protein Scaffolds Partnerships: Most Active Companies
 
Figure 9.1 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Funnel Analysis: Distribution by Target / Marker and Type of Format
 
Figure 9.2 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Grid Analysis: Distribution by Therapeutic Area and Phase of Development
 
Figure 9.3 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Developer Landscape: Distribution by Company Size and Phase of Development
 
Figure 9.4 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Regional Landscape (Industry Players): Distribution by Company Location and Pipeline Strength
 
Figure 9.5 Non-Antibody Protein Scaffold Based Drugs / Diagnostic Leading Players: 3D Bubble Analysis Based on Company Size, Strength of Pipeline and Recent Collaborations
 
Figure 10.1 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market, 2017, 2024, and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
 
Table 3.1 Top Ten Therapeutic Antibodies, 2016
 
Table 3.2 Comparison of Key Characteristics: Monoclonal Antibodies, Antibody-Derived Protein Scaffolds and Non-Antibody Protein Scaffolds
 
Table 4.1 Non-Antibody Protein Scaffolds: Comparison of Structural Features 
 
Table 4.2 Non-Antibody Protein Scaffolds: Comparison of Pharmacokinetic and Biophysical Features
 
Table 4.3 Non-Antibody Protein Scaffolds: Spider-Web Analysis (Input Data)
 
Table 5.1 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Development Pipeline
 
Table 5.2 List of Terminated / Withdrawn Non-Antibody Protein Scaffold Drugs / Diagnostics
 
Table 6.1 Non-Antibody Protein Scaffolds: List of Drugs / Diagnostic Agents Profiled
 
Table 6.2 Kalbitor®: Current Status of Development
 
Table 6.3 Kalbitor®: Clinical Trials
 
Table 6.4 Shire: List of Funding Instances and Investors
 
Table 6.5 Dyax: List of Funding Instances and Investors
 
Table 6.6 Abicipar Pegol: Current Status of Development
 
Table 6.7 Abicipar Pegol: Clinical Trials
 
Table 6.8 Allergan: List of Funding Instances and Investors
 
Table 6.9 RG6206: Current Status of Development
 
Table 6.10 RG6206: Clinical Trials
 
Table 6.11 Roche: List of Funding Instances and Investors
 
Table 6.12 ABY-025: Current Status of Development
 
Table 6.13 ABY-025: Clinical Trials
 
Table 6.14 Affibody: List of Funding Instances and Investors
 
Table 6.15 ABY-035: Current Status of Development
 
Table 6.16 ABY-035: Clinical Trials
 
Table 6.17 MP0250: Current Status of Development
 
Table 6.18 MP0250: Clinical Trials
 
Table 6.19 Molecular Partners: List of Funding Instances and Investors
 
Table 6.20 PRS-080: Current Status of Development
 
Table 6.21 PRS-080: Clinical Trials
 
Table 6.22 Pieris Pharmaceuticals: List of Funding Instances and Investors
 
Table 7.1 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Expected Launch Years of Advanced Stage Drug Candidates
 
Table 7.2 Kalbitor®: Target Patient Population
 
Table 7.3 Abicipar Pegol: Target Patient Population
 
Table 7.4 RG6206: Target Patient Population
 
Table 7.5 MP0250: Target Patient Population
 
Table 7.6 ABY-025: Target Patient Population
 
Table 7.7 ABY-035: Target Patient Population
 
Table 8.1 Non-Antibody Protein Scaffolds: Recent Partnerships
 
Table 12.1 Revenues of the Top 15 Drugs, 2016 (USD Billion)
 
Table 12.2 Non-Antibody Protein Scaffolds: Distribution by Scaffold Class
 
Table 12.3 Non-Antibody Protein Scaffolds: Distribution by Origin of Parent Protein
 
Table 12.4 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Phase of Development
 
Table 12.5 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by End-Use 
 
Table 12.6 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Therapeutic Area
 
Table 12.7 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Type of Format
 
Table 12.8 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Route of Administration
 
Table 12.9 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Non-Antibody Protein Scaffold Technology
 
Table 12.10 Non-Antibody Protein Scaffold Based Drugs / Diagnostics: Distribution by Leading Players
 
Table 12.11 Kalbitor®: Historical Sales, 2011-H1 2017 (USD Million)
 
Table 12.12 Shire: Annual Revenues, 2012-H1 2017 (USD Billion)
 
Table 12.13 Dyax: Annual Revenues, 2010-9M 2015 (USD Million)
 
Table 12.14 Allergan: Annual Revenues, 2011-H1 2017 (USD Billion)
 
Table 12.15 Roche: Annual Revenues, 2012-H1 2017 (CHF Billion)
 
Table 12.16 Affibody: Annual Revenues, 2012- H1 2017 (SEK Million)
 
Table 12.17 Molecular Partners: Annual Revenues, 2011-H1 2017 (USD Million)
 
Table 12.18 Pieris Pharmaceuticals: Annual Revenues, 2013-H1 2017 (USD Million)
 
Table 12.19 Overall Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market, 2017-2030: Base Scenario (USD Billion)
 
Table 12.20 Overall Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market, 2017-2030: Optimistic Scenario (USD Billion)
 
Table 12.21 Overall Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market Conservative Scenario (USD Billion)
 
Table 12.22 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by Therapeutic Area
 
Table 12.23 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by End-Use
 
Table 12.24 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by Non-Antibody Protein Scaffold Technology
 
Table 12.25 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market (USD Billion), 2017, 2024 and 2030 (Base Scenario): Distribution by Drugs
 
Table 12.26 Kalbitor® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.27 Kalbitor® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.28 Kalbitor® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.29 Abicipar Pegol Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.30 Abicipar Pegol Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.31 Abicipar Pegol Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.32 RG6206 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.33 RG6206 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.34 RG6206 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.35 MP0250 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.36 MP0250 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.37 MP0250 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.38 ABY-025 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.39 ABY-025 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.40 ABY-025 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.41 ABY-035 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 12.42 ABY-035 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 12.43 ABY-035 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 12.44 Non-Antibody Protein Scaffolds Partnerships: Cumulative Trend by Year (2012–2017)
 
Table 12.45 Non-Antibody Protein Scaffolds Partnerships: Distribution by Type of Partnership
 
Table 12.46 Non-Antibody Protein Scaffolds Partnerships: Most Popular Non-Antibody Protein Technology
 
Table 12.47 Non-Antibody Protein Scaffolds Partnerships: Most Active Companies
 
Table 12.48 Non-Antibody Protein Scaffold Based Drugs / Diagnostics Market: Conservative, Base and Optimistic Scenario, 2017, 2024 and 2030 (USD Billion)
 
 
The following companies and organizations have been mentioned in the report:
  1. 20/20 NSERC Ophthalmic Materials Network
  2. AbbVie
  3. AbClon
  4. Actavis
  5. AdAlta
  6. Adnexus Therapeutics
  7. Affibody
  8. Affilogic
  9. Agrisera
  10. AlbaNova University Center, Stockholm University
  11. Allergan
  12. Alta Partners
  13. Amunix
  14. Anaphore
  15. AqueSys
  16. Arisaph Pharmaceuticals
  17. ASKA Pharmaceutical
  18. AstraZeneca
  19. Avacta
  20. Avidia
  21. BancBoston Ventures
  22. BattelleCRO
  23. Baxalta
  24. BB Biotech Ventures
  25. Bicycle Therapeutics
  26. BIND Therapeutics
  27. Biogen
  28. Biomedical Radiation Sciences, Uppsala University
  29. BioMedPartners
  30. Biorexis Pharmaceuticals
  31. Bio-Scaffold International
  32. Biotechnology Value Fund
  33. Biotest
  34. Bioverativ
  35. Blueberry Therapeutics
  36. Bristol-Myers Squibb (BMS)
  37. Boehringer Ingelheim
  38. Cancer Research UK
  39. Charter Growth Capital
  40. Chonnam National University
  41. Chugai Pharmaceutical
  42. Cilag International
  43. Clal Biotechnology Industries
  44. CMIC
  45. Colorado State University
  46. Committee for Medicinal Products for Human Use (CHMP)
  47. Complix 
  48. Counter Stroke Consortium
  49. Covagen
  50. Covance
  51. Cubist Pharmaceuticals
  52. CVie Therapeutics
  53. D’Liver
  54. Daewoong Pharmaceuticals
  55. Daiichi Sankyo
  56. Danforth Advisors
  57. Dartmouth-Hitchcock Medical Center
  58. Defiante Farmaceutica
  59. Dyax
  60. Endeavour Vision
  61. Essex Woodlands Health Ventures
  62. EUROCALIN Consortium 
  63. European Medicines Agency (EMA)
  64. Evotec
  65. Ferring Pharmaceuticals
  66. FGK Clinical Research
  67. Forest Laboratories
  68. ForSight VISION5
  69. GailFosler Group 
  70. GE Healthcare
  71. Genentech
  72. Genzyme 
  73. Global Life Sciences
  74. Glythera
  75. GlaxoSmithKline (GSK)
  76. Hambrecht & Quist
  77. HealthCare Ventures
  78. Herlev Hospital
  79. Index Ventures
  80. Infinity Pharmaceuticals
  81. ING Barings Furman Selz
  82. International Biotechnology Trust
  83. Investor Growth Capital
  84. ITM Isotopen Technologien München
  85. J. Goldman & Company
  86. J.P. Morgan Asset Management 
  87. Janssen Biotech
  88. Jefferies & Company
  89. Johnson & Johnson
  90. Katalyst Securities
  91. Kaupthing Bank
  92. Kythera Biopharmaceuticals 
  93. Lee’s Pharmaceutical Holdings
  94. LI-COR Biosciences
  95. Loeb Partners
  96. MedImmune
  97. Memorial Sloan Kettering Cancer Center (MSKCC)
  98. Merck
  99. Mitsubishi Tanabe Pharma 
  100. Moderna Therapeutics
  101. Molecular Partners
  102. Mologic
  103. Monsanto 
  104. MorphoSys
  105. NascaCell Technologies
  106. National Cancer Institute (NCI) 
  107. Navigo Proteins
  108. NC3R
  109. Nectagen
  110. Needham & Company
  111. Neopharm Scientific 
  112. New York Life Insurance Company
  113. Nordic Nanovector
  114. Northland Securities
  115. Northwood Medical Innovation
  116. Novartis
  117. Novellus Biopharma
  118. Nuvisan Pharma Services
  119. OBodies
  120. Ono Pharmaceutical
  121. Owens-Illinois 
  122. Paratek Pharmaceuticals
  123. PhoreMost
  124. Pieris Pharmaceuticals
  125. Pint Pharma
  126. Poseida Therapeutics
  127. ProtATonce
  128. Protelica 
  129. Proteostasis Therapeutics 
  130. Research Corporation Technologies (RCT)
  131. Rho Management Trust
  132. Roche
  133. Sanofi
  134. Schroder Ventures Life Sciences
  135. Selexis
  136. Servier
  137. Shire
  138. Sigma-Tau Group
  139. Sinobioway 
  140. Spencer Stuart
  141. Stanford University
  142. Stelis Biopharma
  143. Strides Arcolab
  144. Swedish Cancer Society
  145. Swedish Orphan Biovitrum (Sobi™)
  146. taiba
  147. Takeda Pharmaceutical 
  148. Technical University of Munich
  149. Teva Pharmaceutical
  150. ThromboGenics
  151. Transposagen Biopharmaceuticals
  152. Trout Capital
  153. UbiQ Bio 
  154. United States Food and Drug Administration (USFDA) 
  155. University of Alberta
  156. University of Leeds
  157. University of Massachusetts
  158. University of Toronto
  159. University of Zurich
  160. UV-Cap
  161. ViiV Healthcare
  162. Winthrop University Hospital
  163. XL-protein
  164. ZELTIQ Aesthetics 
  165. Zydus Cadila

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security